Redirection of SARS-CoV-2 to Phagocytes by Intranasal sACE2-Fc as a Universal Decoy Confers Complete Prophylactic Protection

This study demonstrates that an intranasally administered engineered sACE2-Fc decoy (B5-D3) confers complete prophylactic protection against SARS-CoV-2 in mice by redirecting virus-decoy complexes to airway phagocytes for Fc-dependent lysosomal degradation, thereby establishing a distinct antiviral mechanism that overcomes the limitations of current vaccines and therapies.

The Gist

The Big Picture: A "Universal Trap" for the Virus

Imagine the SARS-CoV-2 virus (the coronavirus) as a master thief trying to break into a house. The "house" is your lung cells, and the "front door" is a specific lock called ACE2. The thief has a special key (the Spike protein) that fits perfectly into this lock to get inside and start causing trouble.

For a long time, scientists tried to stop the thief by making better locks (vaccines) or hiring guards who only recognize specific thieves (monoclonal antibodies). But the thief keeps changing his disguise (mutating), so the guards often miss him.

This paper introduces a new strategy: The "Universal Decoy."

Instead of trying to lock the door, the researchers created a fake door that looks exactly like the real one but is actually a trap. They call this B5-D3. It's a piece of the "lock" (ACE2) floating freely in your nose, waiting to catch the thief's key.

The Problem with Previous "Fake Doors"

Scientists had tried this before with a "fake door" called soluble ACE2. However, it had two major flaws:

1. It was weak: The virus could sometimes still slip past it.
2. It was messy: The fake door had a "sticky" side that accidentally messed up the body's natural plumbing system (the Renin-Angiotensin System), which controls blood pressure.

The Solution: A Super-Refined Trap (B5-D3)

The researchers in this study took the old "fake door" and gave it a minor makeover. They made just two tiny tweaks (mutations):

• Tweak 1: Made the fake door stickier to the virus's key, so the thief grabs the fake door instead of the real one.
• Tweak 2: Removed the "sticky plumbing" part so it doesn't mess up blood pressure.

This new version, B5-D3, is like a high-tech, super-sticky Velcro trap that is safe for the body.

The Secret Weapon: The "Trash Collector" Team

Here is where the study gets really clever. Usually, when a decoy catches a virus, the virus just sits there. But the researchers attached a special tag to their decoy (an Fc tag, which is like a "Handle" or a "Flag").

When the virus grabs the decoy, it doesn't just get stuck; it gets flagged for immediate disposal.

Think of your lungs as a busy city street.

• Without the decoy: The virus walks right into the houses (lung cells) and starts a riot.
• With the decoy: The virus grabs the decoy. The "Handle" on the decoy signals the city's Trash Collectors (immune cells called macrophages).
• The Result: The Trash Collectors see the flag, grab the virus-decoy bundle, and throw it straight into the incinerator (the lysosome) where it is destroyed. The virus never gets to enter the house.

Why the "Nose Spray" Matters

The researchers tested giving this decoy in two ways:

1. IV (Through a vein): Like sending a cleanup crew to the whole city. It helped a little, but the virus was already spreading.
2. IN (Intranasal/Nose spray): Like putting the traps right at the front gate of the city.

The Nose Spray won.
Because the virus enters through the nose, spraying the decoy there creates a "wall of traps" right where the invasion starts. In the mouse experiments, the nose spray group was 100% protected. They didn't get sick, didn't lose weight, and the virus was completely wiped out before it could even start an infection.

The "Immune Alarm" Bonus

The study also found that this process does something else amazing. When the Trash Collectors (macrophages) eat the virus-decoy bundle, they don't just throw it away; they sound an alarm.

This alarm wakes up the rest of the immune system early, telling it, "Hey, we found a virus, get ready!" This happens before the virus can hide and cause damage. It's like the Trash Collectors not only taking out the trash but also turning on the streetlights and calling the police before the thief can even break a window.

Summary of the Findings

• The Design: A simple, safe, two-mutation "fake door" (B5-D3).
• The Delivery: A nose spray (intranasal) is the best way to use it.
• The Mechanism: It catches the virus and flags it for the body's "Trash Collectors" (macrophages) to eat and destroy.
• The Result: Complete protection in mice, even against new, tricky virus variants.

Why This Matters for the Future

This isn't just about stopping the current coronavirus. Because the decoy targets the shape of the virus's key (which hasn't changed much) rather than a specific disguise, it is much harder for the virus to evolve a way to escape it.

It offers a blueprint for a "universal shield" against future respiratory viruses. Instead of waiting for a new vaccine every time a new virus appears, we might be able to spray a universal "decoy" that redirects any virus with a similar key straight to the trash can.

Technical Summary

1. Problem Statement

The rapid evolution of SARS-CoV-2 and other respiratory RNA viruses has led to frequent breakthrough infections, limiting the efficacy of conventional vaccines and monoclonal antibody (mAb) therapies due to immune escape. While soluble angiotensin-converting enzyme 2 (sACE2) decoys offer a promising alternative by acting as viral sinks, previous iterations (e.g., APN01) showed limited clinical success. Furthermore, existing engineered sACE2-Fc variants often suffer from:

• Incomplete protection: Failure to fully prevent infection in animal models.
• Safety concerns: Potential disruption of the endogenous Renin-Angiotensin System (RAS) due to residual enzymatic activity.
• Unclear mechanisms: A lack of understanding regarding how Fc-mediated effector functions contribute to antiviral efficacy beyond simple neutralization.

2. Methodology

The study employed a multi-faceted approach combining protein engineering, in vitro assays, and in vivo mouse models to develop and characterize an optimized sACE2-Fc decoy.

• Protein Engineering:

  • Designed a series of sACE2-Fc mutants based on the human IgG1 Fc fusion scaffold.
  • Binding Enhancement: Introduced the T92Q mutation (B5) to remove a glycosylation site and increase spike-binding affinity.
  • Enzymatic Inactivation: Introduced mutations (e.g., H374N, designated D3) to abolish catalytic activity without compromising spike binding.
  • Selection: Identified B5-D3 (T92Q/H374N) as the optimal candidate, featuring only two mutations to minimize immunogenicity risks.
  • Fc Modification: Created a control variant, B5-D3-LALA, with L234A/L235A mutations to abrogate Fc$\gamma$R binding and effector functions.

• In Vitro Characterization:

  • Neutralization: Tested against pseudoviruses and authentic SARS-CoV-2 (Wuhan-Hu-1, Delta, Omicron sublineages including BA.5, BQ.1.22, and XBB.1.5) using plaque reduction neutralization tests (PRNT) and luciferase assays.
  • Enzymatic Activity: Verified via fluorometric assays to ensure RAS safety.
  • Phagocytosis Assays: Used THP-1 derived macrophages (M0/M1) and Calu-3 epithelial cells to assess viral uptake, lysosomal colocalization (LAMP1), and spike cleavage (S2' fragment).

• In Vivo Models:

  • Safety: Used K18-hACE2 mice injected with AAV vectors for prolonged expression to monitor RAS metabolites (Renin, Ang II, Ang 1-7) and histology.
  • Efficacy: Administered recombinant B5-D3 protein via Intranasal (IN) and Intravenous (IV) routes to aged (10–12 months) and young (2–3 months) K18-hACE2 mice prior to and post-SARS-CoV-2 challenge.
  • Mechanistic Studies:
    • Bio-distribution: Traced Alexa Fluor 750-labeled B5-D3 (B5-D3-AF750) in vivo and ex vivo.
    • Flow Cytometry: Analyzed Bronchoalveolar Lavage Fluid (BALF) to identify specific immune cell uptake.
    • Transcriptomics: RNA-Seq of lung tissues at 1, 2, and 4 days post-infection (dpi) to profile immune activation.

3. Key Contributions

• Optimized Decoy Design: Developed B5-D3, a minimally mutated (2 mutations) sACE2-Fc decoy that balances high neutralization potency with complete enzymatic inactivation, reducing the risk of RAS disruption and immunogenicity.
• Route-Specific Efficacy: Demonstrated that Intranasal (IN) prophylaxis is superior to IV administration, conferring complete protection even at a 6-fold lower dose.
• Novel Mechanism of Action: Uncovered a dual-function mechanism where the decoy not only neutralizes the virus but actively redirects virus-decoy complexes to phagocytes for lysosomal degradation via Fc-mediated effector functions.
• Universal Strategy: Proposed a "decoy strategy" that is intrinsically resistant to antigenic escape, as it targets the conserved ACE2 receptor interaction rather than specific viral epitopes.

4. Key Results

• Potent and Broad Neutralization:

  • B5-D3 exhibited superior neutralization against Wuhan-Hu-1, D614G, and all tested Variants of Concern (VOCs) and Interest (VOIs), including Omicron sublineages (BA.5, BQ.1.22, XBB.1.5).
  • It outperformed the clinical antibody Casirivimab, which failed to neutralize Omicron variants.
  • B5-D3 showed minimal enzymatic activity, whereas wild-type (WT) sACE2-Fc retained significant activity.

• Safety Profile:

  • Prolonged overexpression of B5-D3 in mice via AAV did not disturb serum levels of Renin, Ang II, or Ang (1-7), unlike WT sACE2-Fc which caused RAS disruption.
  • No histological tissue damage was observed in major organs.

• Superior Prophylactic Protection:

  • IN Prophylaxis: In both aged and young K18-hACE2 mice, IN administration of B5-D3 6 hours before challenge resulted in 100% survival and stable body weight, with undetectable viral loads in the lungs.
  • IV Administration: IV treatment (prophylactic or therapeutic) showed only moderate improvement in survival and reduced viral loads but did not achieve complete protection.
  • Therapeutic Limit: Post-infection IN administration (+24h) failed to protect, highlighting the necessity of prophylactic timing.

• Fc-Dependent Mechanism:

  • The B5-D3-LALA mutant (Fc-effector deficient) provided only partial protection and allowed significant viral replication, proving that Fc-mediated effector functions are critical for full efficacy.
  • Phagocytic Clearance: Flow cytometry and confocal microscopy revealed that IN-delivered B5-D3 rapidly accumulates in the respiratory tract and is predominantly taken up by alveolar macrophages (AMs) and monocyte-derived macrophages.
  • Lysosomal Degradation: In macrophages, virus-decoy complexes colocalized with LAMP1 (lysosomes) and were degraded, preventing productive infection. Conversely, in epithelial cells (Calu-3), B5-D3 blocked viral entry.
  • No Productive Infection in Macrophages: Macrophages internalizing the complexes showed no luciferase activity or S2' cleavage, confirming the virus was degraded rather than replicating.

• Early Immune Activation:

  • Transcriptomic analysis (RNA-Seq) of lungs at 1 dpi showed that B5-D3 prophylaxis induced early activation of chemotaxis, antigen presentation, and T-cell differentiation pathways (e.g., Rap1 signaling, Th1/Th2 differentiation) without the massive inflammatory response seen in PBS-treated infected mice.

5. Significance

This study establishes a new paradigm for antiviral decoy therapy:

1. Mechanistic Insight: It moves beyond the concept of simple "neutralization" to demonstrate that sACE2-Fc decoys can function as immune engagers, actively recruiting phagocytes to clear viral particles via Antibody-Dependent Cellular Phagocytosis (ADCP)-like mechanisms.
2. Clinical Translation: The findings support the development of intranasal prophylactics for respiratory viruses. The IN route targets the primary site of infection (respiratory mucosa) and leverages local phagocyte populations for immediate clearance.
3. Future-Proofing: By targeting the host receptor (ACE2) rather than viral epitopes, this strategy offers a robust defense against future variants that may escape antibody-based therapies.
4. Safety: The minimal mutagenesis strategy (only two mutations) addresses safety concerns regarding immunogenicity and RAS interference, paving the way for clinical trials.

In conclusion, the B5-D3 decoy represents a highly effective, safe, and mechanism-driven prophylactic strategy that redirects SARS-CoV-2 to phagocytic clearance, offering a universal solution against evolving respiratory pathogens.